Publication of the REMED study
Recently, a summary of the REMED clinical trial protocol was published in BioMed Central, with the title Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial. The full text of the publication can thus be found on BioMed Central.
REMED study
The national, multicentre REMED clinical trial is being carried out by the University Hospital Brno in cooperation with VI CZECRIN and as of 21. 9. 142 patients out of the planned 300 patients were enrolled in 2021. Patients are enrolled in 7 centres (out of 10 initiated) – FN Brno, FNUSA, FN Královské Vinohrady, FN Plzeň, FN Ostrava, FN Olomouc and Tomáš Bata Regional Hospital Zlín. The initiator and coordinator of the REMED clinical trial is the Deputy Head of the Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, Jan Maláska, MD, PhD, from the University Hospital Brno. The primary objective of the study is to test the hypothesis whether the administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19.